TY - CHAP M1 - Book, Section TI - Chapter 86. Endocrine Therapy A1 - Francis, Prudence A. A2 - Kuerer, Henry M. Y1 - 2010 N1 - T2 - Kuerer's Breast Surgical Oncology AB - Among postoperative therapies for early breast cancer, endocrine therapy is responsible for the greatest reduction in the risk of recurrence and death. Following resection of hormone receptor–positive breast cancer, adjuvant endocrine therapy reduces the risk of local recurrence, distant metastasis, and contralateral breast cancer. Currently new medical oncology treatments described as targeted therapies are improving outcomes in a variety of malignancies. Tamoxifen treatment for breast cancer represents the first successful application of a targeted therapy, where the drug targets the estrogen receptor (ER) on any residual tumor cells. Tamoxifen is described as a selective estrogen receptor modulator (SERM) because of its varying effects in different tissues, where it may act as an antagonist (eg, breast) or an agonist (eg, uterus). SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/11/06 UR - accesssurgery.mhmedical.com/content.aspx?aid=6417023 ER -